Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients

Cystic Fibrosis Clinical Trial

Official title:

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen Days

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01944735
• Other study ID #: CTX-4430-CF-001
• Status: Completed
• Phase: Phase 1
• First received: September 6, 2013
• Last updated: March 4, 2015
• Start date: September 2013
• Est. completion date: November 2014

Study information

• Verified date: March 2015
• Source: Celtaxsys, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Northern Ireland: Office for Research Ethics Committees Northern Ireland (ORECNI)
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of multiple oral doses of CTX-4430 when administered to cystic fibrosis (CF) patients once-daily (QD) for 15 days.This study will include two dose levels. For each dose level, blood samples will be collected for exploratory PK and PD assay validation. In addition, sputum will be collected for exploratory biomarker analysis. Following multiple dose administration, pulmonary function and exploratory lung clearance index (LCI) measurements will be taken.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: November 2014
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Adult male or female, 18 to 55 years of age (inclusive) at the time of screening.

2. Confirmed diagnosis of CF based on the following: positive sweat chloride or sodium value = 60 mEq/L, and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype or a diagnosis of CF made by a specialist in this condition.

3. In the judgment of the Principal Investigator (PI), the patient is medically stable with no change in symptoms, medication, or with clinical laboratory results that in PI opinion are compatible with the diagnosis of either CF or a complication thereof and are judged acceptable for inclusion.

4. Body mass index (BMI) = 17.0 (kg/m2).

5. Non-tobacco/nicotine-containing product user for a minimum of 6 months prior to the first study drug administration.

6. Forced Expiratory Volume (FEV1) of >50% and <90% of predicted at screening.

7. Must agree to use adequate method of contraception.

Exclusion Criteria:

1. Patient has displayed any significant clinical/laboratory/radiological/spirometric sign of unstable or unexpectedly deteriorating respiratory disease within 30 days prior to the first study drug administration.

2. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease that depart from the patient's usual baseline level of health as a patient with CF.

3. Has a history of lung transplantation.

4. History or presence of alcoholism or drug abuse within 2 years prior to the first study drug administration.

5. Personal or family history of prolonged QT syndrome; or a QTc interval >430 msec (males) or >450 msec (females) using Bazett's formula (QTcB) or deemed clinically significant by the PI.

6. Sitting blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg, unless deemed clinically insignificant by the PI.

7. Pulse is higher than 100 b.p.m or lower than 50 b.p.m. unless deemed clinically insignificant by the PI.

8. Failure to satisfy the PI of fitness to participate for any other reason.

9. In the judgment of the PI, clinically significant hemoptysis (>30 cc per episode) within the last 180 days.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Intervention

Drug:
• CTX-4430
Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
• Placebo
Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15

Locations

Country	Name	City	State
United Kingdom	Celerion	Belfast	Northern Ireland
United Kingdom	Glasgow Clinical Research Facility	Glasgow
United Kingdom	Royal Brompton Hospital	London
United Kingdom	The Medicinces Evaluation Unit	Wythenshawe	Manchester

Sponsors (2)

Lead Sponsor	Collaborator
Celtaxsys, Inc.	Celerion

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of the safety and tolerability of multiple oral doses of CTX-4430 when administered to cystic fibrosis (CF) patients once-daily (QD)	Changes in clinical signs and symptoms of safety data that include physical examinations, ECGs, vital signs, pulse oximetry, pulmonary function (spirometry), clinical laboratory results, and adverse events which will be summarized descriptively and reported in tabular form.	15 days	Yes